The US District Court for the District of Delaware’s decision came in the case of Eli Lilly et al v. Teva Parenteral Medicines, et al.
Eli Lilly senior vice president and general counsel Robert Armitage said, "We continue to emphasise that protection of intellectual property rights is extremely important to the biopharmaceutical industry and the patients we serve."
"These rights provide assurances of market exclusivity that help support the development of the next generation of innovative medicines to treat unmet medical needs."
The patent allows protection for Alimta until July 2016.